Clinical lead Euroscreen is advancing ESN364 into clinical development for Women’s Health Disorders, highlighting a potential need for translational collaborations, CROs, and contract manufacturing partners with experience in early-phase oncology and rare disease programs to support further trials and expansion.

Small molecule focus The company specializes in first-in-class small molecule drug candidates targeting G-Protein Coupled Receptors across neurodegenerative diseases, inflammation, and women’s health, presenting licensing, co-development, and discovery collaboration opportunities with larger pharma players seeking novel modalities.

Sustainability signal Recent material innovations such as 100% PVC-free Xpert screen material without hazardous substances demonstrate a commitment to sustainable operations, which can be leveraged in partner discussions with buyers and funders prioritizing ESG-supported supply chains.

Funding and scale With a funding runway of around $31M and revenue in the low tens of millions, Euroscreen presents an opportunity for strategic partnerships, co-development deals, or equity investments to accelerate pipeline progression and expand preclinical and clinical activities.

Collaborative potential Backed by notable investors and a focused small-team structure, Euroscreen may benefit from strategic collaborations with contract research organizations, medicinal chemistry/DS collaborations, or regional licensing deals to access broader resources and accelerate go-to-market timelines.